Arcadia Investment Management Corp MI Has $185,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Arcadia Investment Management Corp MI grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 8,075.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,635 shares of the medical device company’s stock after purchasing an additional 1,615 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in DexCom were worth $185,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter worth about $25,000. DSM Capital Partners LLC acquired a new position in DexCom during the fourth quarter valued at approximately $28,000. Crewe Advisors LLC bought a new stake in DexCom in the first quarter valued at approximately $29,000. Riverview Trust Co bought a new stake in DexCom in the first quarter valued at approximately $32,000. Finally, Smithfield Trust Co raised its holdings in DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after purchasing an additional 165 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 2.4 %

Shares of NASDAQ DXCM traded down $1.66 during trading hours on Friday, hitting $67.39. The company had a trading volume of 588,060 shares, compared to its average volume of 3,774,768. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The firm’s 50 day moving average is $87.55 and its 200-day moving average is $113.28. The stock has a market capitalization of $26.80 billion, a P/E ratio of 44.55, a price-to-earnings-growth ratio of 2.15 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.34 earnings per share. On average, analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Jereme M. Sylvain sold 745 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $85,712.25. Following the sale, the chief financial officer now owns 84,948 shares of the company’s stock, valued at $9,773,267.40. The disclosure for this sale can be found here. In the last three months, insiders sold 3,483 shares of company stock worth $369,052. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

DXCM has been the subject of several research analyst reports. Stifel Nicolaus boosted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Oppenheimer decreased their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. Redburn Atlantic initiated coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target on the stock. Baird R W lowered DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Finally, UBS Group lowered their target price on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.